



SmartPA Criteria Proposal

Drug/Drug Class:	Corticosteroids, Topical PDL Edit	
First Implementation Date:	June 21, 2012	
Revised Date:	July 7, 2022	
Prepared For:	MO HealthNet	
Prepared By:	MO HealthNet/Conduent	
Criteria Status:	 Existing Criteria Revision of Existing Criteria New Criteria 	

Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Topical corticosteroids are used for a variety of inflammatory skin conditions, including Selected: atopic dermatitis, seborrheic dermatitis, eczema, and plaque psoriasis. Pharmacotherapy choices for these conditions typically include emollients and topical corticosteroids. Emollients play an important role in the treatment of atopic dermatitis; however, topical steroids are the standard of care to which other treatments are compared. The selected potency should depend on the severity and location of disease. These agents control symptoms such as swelling, skin cracking, weeping, crusting, and scaling. This PDL class includes all potency classes and does not require additional criteria to gain access to or move from one group to another.

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific	Preferred Agents	Non-Preferred Agents
Information:	Anusol-HC [®]	Ala-Scalp [®]
	Betamethasone Dip Lot	Alclometasone Dip
	 Betamethasone Val Crm/Lot/Oint 	Amcinonide
	Clobetasol Emollient Crm	Apexicon E [®]
	Clobetasol Prop Crm/Gel/Oint/Soln	Aqua Glycolic [®] HC Kit
	Fluocinolone Scalp Oil	 Beser[™]
	Fluticasone Prop Crm/Oint	Betamethasone Dip Aug Crm/Gel/Lot/
	Hydrocortisone Crm/Lot/Oint Rx	Oint
	Hydrocortisone Crm/Oint OTC	Betamethasone Dip Crm/Oint
	Mometasone	Betamethasone Val Foam
	 Procto-Med HC[™] 	Bryhali [®]
	• Proctosol-HC [®]	• Capex [®]
	Proctozone-HC [®]	Clobetasol Emollient Foam
	Triamcinolone Crm/Lot/Oint (excluding	Clobetasol Prop Foam/Lot/Shampoo/
	gen Trianex®)	Spray
		• Clobex [®]
		Clocortolone
		Clodan [®]
		Cloderm [®]

SmartPA PDL Proposal Form

 \circledcirc 2022 Conduent Business Services, LLC. All rights reserved. Conduent^M and Conduent Design[™] are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Cordran [®]
Cutivate [®]
Derma-Smoothe/FS [®]
Dermatop [®]
Desonate [®]
Desonide
Desowen [®]
Desoximetasone
Diflorasone Crm/Oint
Diprolene [®]
Elocon [®]
Fluocinolone Body Oil/Crm/Oint/Soln
 Fluocinonide
Fluocinonide Emollient
 Flurandrenolide
 Fluticasone Prop Lot Halcinonide
Halog [®]
Hydrocortisone Absorbase Rx
Hydrocortisone Butyrate
Hydrocortisone Lot OTC
Hydrocortisone Valerate
Hydrocortisone/Aloe
• Impoyz [®]
• Kenalog [®]
• Lexette [®]
Locoid [®]
Locoid Lipocream [®]
• Luxiq [®]
Micort-HC [®]
• Nolix [®]
 Nucort[™]
• Olux [®]
• Olux-E [®]
• Pandel [®]
Pediaderm [®]
Prednicarbate
 Procto-Pak[™]
Psorcon [®]
Sernivo [®]
Synalar [®]
Temovate [®]
• Texacort [®]
• Topicort [®]
• Tovet [®]
Triamcinolone 0.05% Oint (gen
Trianex [®])
Triamcinolone Acet Aerosol
• Trianex®
 Triderm[™]
• Tridesilon®

SmartPA PDL Proposal Form © 2022 Conduent Business Services, LLC. All rights reserved. Conduent[™] and Conduent Design[™] are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

		 Ultravate[®] Ultravate[®] X Vanos[®] Verdeso[®]
Type of Criteria:	 ☐ Increased risk of ADE ☐ Appropriate Indications 	☑ Preferred Drug List □ Clinical Edit

☑ Databases + Prescriber-Supplied

Data Sources:

Only Administrative Databases

Setting & Population

- Drug class for review: Corticosteroids, Topical
- Age range: All appropriate MO HealthNet participants

Approval Criteria

- · Failure to achieve desired therapeutic outcomes with trial on 4 or more preferred agents
 - Documented trial period of preferred agents OR
 - Documented ADE/ADR to preferred agents

Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if all approval criteria are not met

Required Documentation

Laboratory Results: MedWatch Form: Progress Notes: Other:

Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List) Rule Type: PDL

Default Approval Period

1 year

References

- Evidence-Based Medicine and Fiscal Analysis: "Topical Corticosteroids Therapeutic Class Review", Conduent Business Services, L.L.C., Richmond, VA; January 2022.
- Evidence-Based Medicine Analysis: "Topical Corticosteroids", UMKC-DIC; January 2022.
- USPDI, Micromedex; 2022.
- Facts and Comparisons eAnswers (online); 2022 Clinical Drug Information, LLC.

SmartPA PDL Proposal Form © 2022 Conduent Business Services, LLC. All rights reserved. Conduent[™] and Conduent Design[™] are trademarks of Conduent Business Services, LLC in the United States and/or other countries.